Mid-cap Health Care company Jazz Pharmaceuticals has logged a 0.4% change today on a trading volume of 302,712. The average volume for the stock is 482,067.
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. Based in Dublin, Ireland the company has 2,800 full time employees and a market cap of $8,092,767,232.
The company is now trading -36.98% away from its average analyst target price of $200.65 per share. The 17 analysts following the stock have set target prices ranging from $165.0 to $240.0, and on average give Jazz Pharmaceuticals a rating of buy.
Over the last year, JAZZ shares have gone down by -15.9%, which represents a difference of -18.0% when compared to the S&P 500. The stock's 52 week high is $163.31 per share and its 52 week low is $125.35. With its operating margins declining a compounded average of -17.1% over the last 4 years, Jazz Pharmaceuticals may not have a strong enough business to reverse this trend.